Voso Maria Teresa, Ferrara Felicetto, Galimberti Sara, Rambaldi Alessandro, Venditti Adriano
Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
Division of Hematology, Cardarelli Hospital, Naples, Italy.
Front Oncol. 2022 Feb 17;12:828072. doi: 10.3389/fonc.2022.828072. eCollection 2022.
Acute myeloid leukemia (AML) is a heterogeneous disease with a wide variety of clinical presentations, morphological features, and immunophenotypes. The diagnostic approaches to AML that are adopted in Italy have been explored using an online Delphi-based process to expand the global discussion on mandatory tests for the correct diagnosis and, consequently, for optimal management of AML in clinical practice. The final results of the panel of Italian hematologists involved in this work highlight the importance of genetic evaluation for classification and risk stratification and firmly establish that karyotyping, fluorescence hybridization in cases with non-evaluable karyotype, and molecular tests must be performed in every case of AML, regardless of age. Obtaining clinically relevant genetic data at diagnosis is the basis for the success of patient-tailored therapy. The Italian specialists also confirm the role of multidisciplinary diagnostics for AML, now mandatory and expected to become more important in the future context of "precision" medicine.
急性髓系白血病（AML）是一种具有多种临床表现、形态学特征和免疫表型的异质性疾病。意大利采用的AML诊断方法已通过基于德尔菲法的在线流程进行了探索，以扩大关于正确诊断所需的强制性检测以及因此在临床实践中对AML进行最佳管理的全球讨论。参与这项工作的意大利血液学家小组的最终结果强调了基因评估对分类和风险分层的重要性，并明确规定，无论年龄大小，每例AML患者都必须进行核型分析、对核型不可评估的病例进行荧光杂交以及分子检测。在诊断时获取临床相关的基因数据是患者个体化治疗成功的基础。意大利专家还证实了多学科诊断对AML的作用，现在这是强制性的，并且预计在未来“精准”医学背景下会变得更加重要。
